Pub Date : 2019-09-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.05.003
Mengying Zhang, Huaquan Wang
Neutrophils are one of the most important cells in the body against bacterial and fungal infections. Patients with acute leukemia who received radiotherapy, chemotherapy or hematopoietic stem cell transplantation (HSCT), and with severe aplastic anemia (SAA), can occur with severe neutropenia that lasts longer, during which severe bacterial and fungal infections can occur. Despite the use of broad-spectrum antibacterial agents and granulocyte colony-stimulating factor (G-CSF), severe infections during neutropenia still lead to prolonged hospital stay, organ damage, and even death of patients. The recovery of bone marrow granulocyte hematopoiesis is the key to successful infection control. For patients with severe infections of granulocytopenia, especially agranulocytosis, granulocyte transfusions is a means of adjuvant therapy. In order to understand the role and indications of granulocyte transfusions, the article intends to introduce the collection technology of granulocyte, therapeutic effect and adverse reactions of granulocyte transfusions. Key words: Neutropenia; Agranulocytosis; Granulocyte colony-stimulating factors; Infection; Granulocyte transfusions; Neutrophil dysfunction
{"title":"Research status of granulocyte transfusions","authors":"Mengying Zhang, Huaquan Wang","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.05.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.003","url":null,"abstract":"Neutrophils are one of the most important cells in the body against bacterial and fungal infections. Patients with acute leukemia who received radiotherapy, chemotherapy or hematopoietic stem cell transplantation (HSCT), and with severe aplastic anemia (SAA), can occur with severe neutropenia that lasts longer, during which severe bacterial and fungal infections can occur. Despite the use of broad-spectrum antibacterial agents and granulocyte colony-stimulating factor (G-CSF), severe infections during neutropenia still lead to prolonged hospital stay, organ damage, and even death of patients. The recovery of bone marrow granulocyte hematopoiesis is the key to successful infection control. For patients with severe infections of granulocytopenia, especially agranulocytosis, granulocyte transfusions is a means of adjuvant therapy. In order to understand the role and indications of granulocyte transfusions, the article intends to introduce the collection technology of granulocyte, therapeutic effect and adverse reactions of granulocyte transfusions. \u0000 \u0000 \u0000Key words: \u0000Neutropenia; Agranulocytosis; Granulocyte colony-stimulating factors; Infection; Granulocyte transfusions; Neutrophil dysfunction","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"380-386"},"PeriodicalIF":0.0,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47087830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.05.007
Man-hua Zhang, Hong-Gang Ren, C. Luo, Jian-min Wang, C. Luo, Jian Wang, J. Chen
Objective To explore the clinical characteristics of transfusion associated graft-versus-host disease (TA-GVHD) of children. Methods On July 31, 2017, a 2-month-old male infant with TA-GVHD who was admitted to Shanghai Children′s Medical Center was selected as research subject into this study.Retrospective analysis was made on the clinical case data of the child and the clinical characteristics were summarized. " Transfusion associated graft-versus host disease" in Chinese and English respectively were used as key words in order to retrieve literature from China National Knowledge Infrastructure Database and Wanfang Database, as well as PubMed Database from establishment of database to December 2017. The characteristics, diagnosis, treatment and prognosis of children with TA-GVHD were summarized by reviewing related literature. The procedures followed in this study were in accordance with the requirements of the World Medical Association Declaration of Helsinki revised in 2013. Results ① This infant was a 2-month-old boy. Because of severe anemia due to infection, he received a non-irradiated erythrocyte transfusion from an unrelated donor before diagnosis of severe combined immunodeficiency. After the last blood transfusion, he presented with the clinical manifestations of fever, rash, diarrhea, elevated direct bilirubin, and hypoproliferative pancytopenia. The results of short tandem repeats (STR)-PCR showed that the genotypes of STR in oral epithelial tissue and blood samples were different, which suggested that there was a donor-derived cell implantation in the blood of the infant, and he was diagnosed as TA-GVHD. Through the results of immunodeficiency-related genes detection, the infant was finally diagnosed as severe combined immunodeficiency disease with TA-GVHD caused by X-linked IL2RG gene deficiency. ② Despite the active anti-infective and immunosuppressive therapy, the TA-GVHD infant died of sepsis and multiple organ failure 31 days after transfusion finally. ③ Literature review results indicated that the main underlying diseases of TA-GVHD in children were neonatal diseases and severe combined immunodeficiency diseases, presenting with fever, rash, elevated direct bilirubin, and hypoproliferative pancytopenia. Conclusions TA-GVHD is a rare, usual fatal, complication after receipt of any cellular blood component with viable lymphocytes. The clinical manifestations of TA-GVHD are lack of specificity, and the symptoms are easily concealed by primary diseases. If the clinicians does not know enough about this disease, it is prone to missed diagnosis. Therefore, clinicians should pay more attention to this disease. Key words: Blood transfusion; Graft vs host disease; Infant, newborn; Child; Severe combined immunedeficiency; γirradiation
{"title":"Transfusion associated graft-versus-host disease of children: a case report and literature review","authors":"Man-hua Zhang, Hong-Gang Ren, C. Luo, Jian-min Wang, C. Luo, Jian Wang, J. Chen","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.05.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.007","url":null,"abstract":"Objective \u0000To explore the clinical characteristics of transfusion associated graft-versus-host disease (TA-GVHD) of children. \u0000 \u0000 \u0000Methods \u0000On July 31, 2017, a 2-month-old male infant with TA-GVHD who was admitted to Shanghai Children′s Medical Center was selected as research subject into this study.Retrospective analysis was made on the clinical case data of the child and the clinical characteristics were summarized. \" Transfusion associated graft-versus host disease\" in Chinese and English respectively were used as key words in order to retrieve literature from China National Knowledge Infrastructure Database and Wanfang Database, as well as PubMed Database from establishment of database to December 2017. The characteristics, diagnosis, treatment and prognosis of children with TA-GVHD were summarized by reviewing related literature. The procedures followed in this study were in accordance with the requirements of the World Medical Association Declaration of Helsinki revised in 2013. \u0000 \u0000 \u0000Results \u0000① This infant was a 2-month-old boy. Because of severe anemia due to infection, he received a non-irradiated erythrocyte transfusion from an unrelated donor before diagnosis of severe combined immunodeficiency. After the last blood transfusion, he presented with the clinical manifestations of fever, rash, diarrhea, elevated direct bilirubin, and hypoproliferative pancytopenia. The results of short tandem repeats (STR)-PCR showed that the genotypes of STR in oral epithelial tissue and blood samples were different, which suggested that there was a donor-derived cell implantation in the blood of the infant, and he was diagnosed as TA-GVHD. Through the results of immunodeficiency-related genes detection, the infant was finally diagnosed as severe combined immunodeficiency disease with TA-GVHD caused by X-linked IL2RG gene deficiency. ② Despite the active anti-infective and immunosuppressive therapy, the TA-GVHD infant died of sepsis and multiple organ failure 31 days after transfusion finally. ③ Literature review results indicated that the main underlying diseases of TA-GVHD in children were neonatal diseases and severe combined immunodeficiency diseases, presenting with fever, rash, elevated direct bilirubin, and hypoproliferative pancytopenia. \u0000 \u0000 \u0000Conclusions \u0000TA-GVHD is a rare, usual fatal, complication after receipt of any cellular blood component with viable lymphocytes. The clinical manifestations of TA-GVHD are lack of specificity, and the symptoms are easily concealed by primary diseases. If the clinicians does not know enough about this disease, it is prone to missed diagnosis. Therefore, clinicians should pay more attention to this disease. \u0000 \u0000 \u0000Key words: \u0000Blood transfusion; Graft vs host disease; Infant, newborn; Child; Severe combined immunedeficiency; γirradiation","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"407-412"},"PeriodicalIF":0.0,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47529088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.05.004
X. Qin, X. Ge, Ze-Fu Li, Caixia Zhang, Linhua Yang
Objective To explore the efficacy and prognostic factors of induction therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Methods From November 2013 to November 2018, a total of 52 newly diagnosed adult patients with Ph+ ALL who admitted to the Department of Hematology, Second Hospital of Shanxi Medical University were included in this study. According to different induction treatment regimens, they were divided into chemotherapy combined with tyrosine kinase inhibitor (TKI) group (n=33) and chemotherapy alone group (n=19). Retrospective analysis method was used to collect the complete remission (CR) rate, no complete remission (NR) rate, recurrence rate, prognosis, and the influencing factors of prognosis in adult patients with Ph+ ALL. The chi-square test was used to compare the CR rates between two groups. The Kaplan-Meier method was used to draw the survival curves. Univariate analysis was performed by Log-rank test to determine the influencing factors affecting the prognosis of patients, such as gender, age, hepatosplenomegaly and white blood cell count and so on. Statistically significant factors and factors with clinical guiding significance in the univariate analysis were included in the Cox proportional hazard regression model for multivariate analysis. The follow-up period was up to November 30, 2018. The procedure of this study was accordance with the requirement of the revised World Medical Association Declaration of Helsinki in 2013. Informed consent was obtained from all participants. Results ① Among the 52 patients with newly diagnosed Ph+ ALL, 36 patients (69.2%) achieved CR and 16 patients (30.8%) achieved NR after 4 weeks induction therapy. The CR rate was 83.3% (30/33) in the chemotherapy combined with TKI group, which was higher than that of 16.7% (6/19) in the chemotherapy alone group, and the difference was statistically significant (χ2=17.237, P<0.001). ② The recurrence rate of the 52 patients in this study was 69.2% (36/52), and the median time to recurrence was 9 months (1-49 months). ③ The median survival time of the 52 patients in this study was 11 months(4-52 months), the 1-year overall survival (OS) rate was 42.3%, and the 1-year event-free survival (EFS) rate was 32.8%. ④ Results of univariate analysis showed that the median EFS rate and OS rate of patients with TKI were 11.0% (95%CI: 9.3%-12.7%) and 11.0% (95%CI: 10.1%-11.8%), respectively, which were higher than those of 6.0% (95%CI: 5.0%-7.0%) and 9.0% (95%CI: 7.6%-10.4%) in patients without TKI, and the differences were statistically significant (χ2=19.021, P<0.001; χ2=11.894, P<0.001). The median EFS rate and OS rate of CR patients after 4 weeks induction chemotherapy were 10.0% (95%CI: 7.7%-12.4%) and 11.0% (95%CI: 10.3%-11.9%), respectively, which were higher than those of 6.0% (95%CI: 4.7%-7.3%) and 9.0% (95%CI: 7.0%-11.0%) in NR patients, the differences were also statistically significant (χ2=
{"title":"Clinical analysis of 52 cases of adult patients with Philadelphia chromosomal-positive acute lymphoblastic leukemia","authors":"X. Qin, X. Ge, Ze-Fu Li, Caixia Zhang, Linhua Yang","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.05.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.004","url":null,"abstract":"Objective \u0000To explore the efficacy and prognostic factors of induction therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). \u0000 \u0000 \u0000Methods \u0000From November 2013 to November 2018, a total of 52 newly diagnosed adult patients with Ph+ ALL who admitted to the Department of Hematology, Second Hospital of Shanxi Medical University were included in this study. According to different induction treatment regimens, they were divided into chemotherapy combined with tyrosine kinase inhibitor (TKI) group (n=33) and chemotherapy alone group (n=19). Retrospective analysis method was used to collect the complete remission (CR) rate, no complete remission (NR) rate, recurrence rate, prognosis, and the influencing factors of prognosis in adult patients with Ph+ ALL. The chi-square test was used to compare the CR rates between two groups. The Kaplan-Meier method was used to draw the survival curves. Univariate analysis was performed by Log-rank test to determine the influencing factors affecting the prognosis of patients, such as gender, age, hepatosplenomegaly and white blood cell count and so on. Statistically significant factors and factors with clinical guiding significance in the univariate analysis were included in the Cox proportional hazard regression model for multivariate analysis. The follow-up period was up to November 30, 2018. The procedure of this study was accordance with the requirement of the revised World Medical Association Declaration of Helsinki in 2013. Informed consent was obtained from all participants. \u0000 \u0000 \u0000Results \u0000① Among the 52 patients with newly diagnosed Ph+ ALL, 36 patients (69.2%) achieved CR and 16 patients (30.8%) achieved NR after 4 weeks induction therapy. The CR rate was 83.3% (30/33) in the chemotherapy combined with TKI group, which was higher than that of 16.7% (6/19) in the chemotherapy alone group, and the difference was statistically significant (χ2=17.237, P<0.001). ② The recurrence rate of the 52 patients in this study was 69.2% (36/52), and the median time to recurrence was 9 months (1-49 months). ③ The median survival time of the 52 patients in this study was 11 months(4-52 months), the 1-year overall survival (OS) rate was 42.3%, and the 1-year event-free survival (EFS) rate was 32.8%. ④ Results of univariate analysis showed that the median EFS rate and OS rate of patients with TKI were 11.0% (95%CI: 9.3%-12.7%) and 11.0% (95%CI: 10.1%-11.8%), respectively, which were higher than those of 6.0% (95%CI: 5.0%-7.0%) and 9.0% (95%CI: 7.6%-10.4%) in patients without TKI, and the differences were statistically significant (χ2=19.021, P<0.001; χ2=11.894, P<0.001). The median EFS rate and OS rate of CR patients after 4 weeks induction chemotherapy were 10.0% (95%CI: 7.7%-12.4%) and 11.0% (95%CI: 10.3%-11.9%), respectively, which were higher than those of 6.0% (95%CI: 4.7%-7.3%) and 9.0% (95%CI: 7.0%-11.0%) in NR patients, the differences were also statistically significant (χ2=","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"387-393"},"PeriodicalIF":0.0,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44047724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.05.014
Runhong Bi, A. Sun
Spliceosome mutations play an important role in the occurrence and development of myelodysplastic syndrome (MDS). The related mutations include SF3B1, U2AF1 (U2AF35), SRSF2, ZRSR2, SF1, SF3A1 and U2AF2 gene mutation. Further understanding of mRNA splicing has a guiding role in the targeted therapy and prognosis of MDS. 70%~85% low rick myelodysplastic syndrome with ringed sideroblasts (MDS-RS) is associated with SF3B1 gene mutation. A number of studies have shown a significant correlation between SF3B1 gene mutation and prognosis of MDS-RS patients. The authors review the latest research progress of relationship between SF3B1 gene mutation and MDS-RS, and the treatment and prognosis of MDS-RS patients with SF3B1 gene mutation. Key words: Myelodysplastic syndrome; Spliceosomes; RNA splicing factors; Mutations; Splicing factor 3 subunit 1 gene; Ringed sideroblast
{"title":"Research progress of SF3B1 gene mutation in myelodysplastic syndrome with ringed sideroblasts","authors":"Runhong Bi, A. Sun","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.05.014","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.014","url":null,"abstract":"Spliceosome mutations play an important role in the occurrence and development of myelodysplastic syndrome (MDS). The related mutations include SF3B1, U2AF1 (U2AF35), SRSF2, ZRSR2, SF1, SF3A1 and U2AF2 gene mutation. Further understanding of mRNA splicing has a guiding role in the targeted therapy and prognosis of MDS. 70%~85% low rick myelodysplastic syndrome with ringed sideroblasts (MDS-RS) is associated with SF3B1 gene mutation. A number of studies have shown a significant correlation between SF3B1 gene mutation and prognosis of MDS-RS patients. The authors review the latest research progress of relationship between SF3B1 gene mutation and MDS-RS, and the treatment and prognosis of MDS-RS patients with SF3B1 gene mutation. \u0000 \u0000 \u0000Key words: \u0000Myelodysplastic syndrome; Spliceosomes; RNA splicing factors; Mutations; Splicing factor 3 subunit 1 gene; Ringed sideroblast","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"446-449"},"PeriodicalIF":0.0,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44897830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.05.011
Xin Yan, Ze-feng Xu
Myelofibrosis(MF) is a type of myeloproliferative neoplasms which is difficult to be treated. With the discovery of V617F mutation in Janus kinase(JAK)2, JAK inhibitor provides a new treatment strategy for patients with myelofibrosis.Ruxolitinib is the first JAK1/2 inhibitor which approved by the Food and Drug Administration(FDA) for the treatment of patients with international prognostic scoring system(IPSS)intermediate-2 or high risk myelofibrosis. In clinical experiments, ruxolitinib demonstrates significant improvements in splenomegaly and disease-related constitutional symptoms, and prolongs patients′ overall survival. However, the side effects of the drug (hematocytopenia, infections and secondary neoplasms) and treatment failure of some patients has been observed in treatments. The adverse reaction and solutions of ruxlitinib; the definition, reason, high risk factors and prognosis of treatment failure; the salvage therapy after treatment failure will be discussed in this review. Key words: Primary myelofibrosis; Janus kinases; Treatment failure; Salvage therapy; Adverse reaction; Ruxolitinib
{"title":"Ruxolitinib in myelofibrosis: solutions for side effects and treatment failure","authors":"Xin Yan, Ze-feng Xu","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.05.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.011","url":null,"abstract":"Myelofibrosis(MF) is a type of myeloproliferative neoplasms which is difficult to be treated. With the discovery of V617F mutation in Janus kinase(JAK)2, JAK inhibitor provides a new treatment strategy for patients with myelofibrosis.Ruxolitinib is the first JAK1/2 inhibitor which approved by the Food and Drug Administration(FDA) for the treatment of patients with international prognostic scoring system(IPSS)intermediate-2 or high risk myelofibrosis. In clinical experiments, ruxolitinib demonstrates significant improvements in splenomegaly and disease-related constitutional symptoms, and prolongs patients′ overall survival. However, the side effects of the drug (hematocytopenia, infections and secondary neoplasms) and treatment failure of some patients has been observed in treatments. The adverse reaction and solutions of ruxlitinib; the definition, reason, high risk factors and prognosis of treatment failure; the salvage therapy after treatment failure will be discussed in this review. \u0000 \u0000 \u0000Key words: \u0000Primary myelofibrosis; Janus kinases; Treatment failure; Salvage therapy; Adverse reaction; Ruxolitinib","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"429-434"},"PeriodicalIF":0.0,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43559901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.05.009
Jing Li, Yunqing Shen
Objective To investigate the correlation between immunoglobulin (Ig) G anti-A/B titer and neonatal hemolytic disease (HDN) in pregnant women with O blood group from ABO blood group incompatibility couples. Methods From February 2015 to August 2017, a total of 104 pregnant women with O-type and Rh-positive blood group who underwent prenatal blood group antibody test because of couples with ABO blood group incompatibility in the Blood Type Reference Laboratory of Blood Center Shandong Province were selected as subjects. The average age of pregnant women were (26.5±6.8) years. According to gravidity of these pregnant women, they were divided into 3 groups : first pregnancy group (n=31), twice pregnancy group (n=35) and≥3 times pregnancy group (n=38). Micro-column method were performed to detect the ABO blood group of the couples, the Rh blood group and titer of serum IgG anti-A/B of pregnant women. The umbilical vein blood samples of newborns were tested by direct anti-globulin test, free antibody test and antibody elution test. The positive rate of serum IgG anti-A/B in pregnant women, the incidence of ABO-HDN in newborns, as well as the correlation among gravidity, serum IgG anti-A/B titer and incidence of ABO-HDN were calculated, respectively. The age and gestational age of pregnant women among 3 groups were compared by variance analysis. The positive rate of serum IgG anti-A/B of pregnant women among 3 groups, and the incidence of ABO-HDN of newborns among different maternal serum IgG anti-A/B titer, were compared by chi-square test, respectively. And further pairwise comparison of above data used Bonferroni method to adjust the significance level. The correlation among the gravidity maternal, serum IgG anti-A/B titer, and neonatal ABO-HDN incidence were analyzed with Spearman rank correlation analysis. The procedures followed in this study were in accordance with the standards established by the Medical Ethics Committee of Blood Center Shandong Province, and this study was approved by the committee. All the subjects signed the informed consents for clinical trials. Results ① In this study, ABO blood group of all 104 pregnant women were O-type, and Rh blood group were positive. The ABO blood group of their husbands included 41 cases of A-type, 48 cases of B-type and 15 cases of AB-type. The ABO blood group of the newborns included 45 cases of A-type, 50 cases of B-type and 9 cases of O-type. ② Among the 104 pregnant women in this study, the total positive rate of serum IgG anti-A/B was 65.4% (68/104). The positive rates of serum IgG anti-A/B of pregnant women in the first, twice, ≥3 times pregnancy groups were 45.2% (14/31), 65.7% (23/35) and 81.6% (31/38), respectively. The overall difference was statistically significant among the 3 groups (χ2=10.007, P=0.008). The positive rate of serum IgG anti-A/B of pregnant women in the ≥3 times pregnancy group was higher than that of the first pregnancy group, and the difference was statisti
{"title":"Correlation between immunoglobulin G anti-A/B titer and neonatal hemolytic disease in pregnant women with O-type blood group from ABO blood group incompatibility couples","authors":"Jing Li, Yunqing Shen","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.05.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.009","url":null,"abstract":"Objective \u0000To investigate the correlation between immunoglobulin (Ig) G anti-A/B titer and neonatal hemolytic disease (HDN) in pregnant women with O blood group from ABO blood group incompatibility couples. \u0000 \u0000 \u0000Methods \u0000From February 2015 to August 2017, a total of 104 pregnant women with O-type and Rh-positive blood group who underwent prenatal blood group antibody test because of couples with ABO blood group incompatibility in the Blood Type Reference Laboratory of Blood Center Shandong Province were selected as subjects. The average age of pregnant women were (26.5±6.8) years. According to gravidity of these pregnant women, they were divided into 3 groups : first pregnancy group (n=31), twice pregnancy group (n=35) and≥3 times pregnancy group (n=38). Micro-column method were performed to detect the ABO blood group of the couples, the Rh blood group and titer of serum IgG anti-A/B of pregnant women. The umbilical vein blood samples of newborns were tested by direct anti-globulin test, free antibody test and antibody elution test. The positive rate of serum IgG anti-A/B in pregnant women, the incidence of ABO-HDN in newborns, as well as the correlation among gravidity, serum IgG anti-A/B titer and incidence of ABO-HDN were calculated, respectively. The age and gestational age of pregnant women among 3 groups were compared by variance analysis. The positive rate of serum IgG anti-A/B of pregnant women among 3 groups, and the incidence of ABO-HDN of newborns among different maternal serum IgG anti-A/B titer, were compared by chi-square test, respectively. And further pairwise comparison of above data used Bonferroni method to adjust the significance level. The correlation among the gravidity maternal, serum IgG anti-A/B titer, and neonatal ABO-HDN incidence were analyzed with Spearman rank correlation analysis. The procedures followed in this study were in accordance with the standards established by the Medical Ethics Committee of Blood Center Shandong Province, and this study was approved by the committee. All the subjects signed the informed consents for clinical trials. \u0000 \u0000 \u0000Results \u0000① In this study, ABO blood group of all 104 pregnant women were O-type, and Rh blood group were positive. The ABO blood group of their husbands included 41 cases of A-type, 48 cases of B-type and 15 cases of AB-type. The ABO blood group of the newborns included 45 cases of A-type, 50 cases of B-type and 9 cases of O-type. ② Among the 104 pregnant women in this study, the total positive rate of serum IgG anti-A/B was 65.4% (68/104). The positive rates of serum IgG anti-A/B of pregnant women in the first, twice, ≥3 times pregnancy groups were 45.2% (14/31), 65.7% (23/35) and 81.6% (31/38), respectively. The overall difference was statistically significant among the 3 groups (χ2=10.007, P=0.008). The positive rate of serum IgG anti-A/B of pregnant women in the ≥3 times pregnancy group was higher than that of the first pregnancy group, and the difference was statisti","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"420-424"},"PeriodicalIF":0.0,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48707791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.05.016
Xinying Zhu
CD7 molecule is a 40 kDa single-chain glycoprotein molecule, belonging to the immunoglobulin superfamily. It is an important surface marker on the human immune cell membrane and plays a role in synergistic stimulation of molecular receptors during lymphocyte development and maturation. As an abnormal marker on the surface of hematological malignant cells, it is highly expressed in acute T-lymphocytic leukemia(T-ALL)and T-cell lymphoma. About 30% of patients with acute myeloid leukemia(AML) have been detected the expression of CD7 antigen in tumor cells. CD7 molecule is thought to be involved with disease invasiveness, drug resistance, and poor prognosis. Potent chemotherapy, immunotherapy, hematopoietic stem cell transplantation(HSCT) and other programs have achieved very significant results in the treatment of hematologic malignant diseases. Despite this, there are still some cases of acquired treatment tolerance during the treatment. Molecular targeted therapy provides a safe, effective, and specific therapy regimen that has received increasing attention in recent years. Using of CD7 molecular as a new target for molecular targeted anti-tumor therapy may provide a new therapeutic direction for CD7-positive relapse or refractory hematological malignant diseases. The article intends to review the current progress in the basic and clinical research of CD7 molecules. Key words: Antigens, CD7; Hematologic neoplasms; Immunotherapy; Molecular targeted therapy; Chimeric antigen receptor
{"title":"Basis of CD7 molecule and its research progress on immunotherapy in hematologic malignant diseases","authors":"Xinying Zhu","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.05.016","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.016","url":null,"abstract":"CD7 molecule is a 40 kDa single-chain glycoprotein molecule, belonging to the immunoglobulin superfamily. It is an important surface marker on the human immune cell membrane and plays a role in synergistic stimulation of molecular receptors during lymphocyte development and maturation. As an abnormal marker on the surface of hematological malignant cells, it is highly expressed in acute T-lymphocytic leukemia(T-ALL)and T-cell lymphoma. About 30% of patients with acute myeloid leukemia(AML) have been detected the expression of CD7 antigen in tumor cells. CD7 molecule is thought to be involved with disease invasiveness, drug resistance, and poor prognosis. Potent chemotherapy, immunotherapy, hematopoietic stem cell transplantation(HSCT) and other programs have achieved very significant results in the treatment of hematologic malignant diseases. Despite this, there are still some cases of acquired treatment tolerance during the treatment. Molecular targeted therapy provides a safe, effective, and specific therapy regimen that has received increasing attention in recent years. Using of CD7 molecular as a new target for molecular targeted anti-tumor therapy may provide a new therapeutic direction for CD7-positive relapse or refractory hematological malignant diseases. The article intends to review the current progress in the basic and clinical research of CD7 molecules. \u0000 \u0000 \u0000Key words: \u0000Antigens, CD7; Hematologic neoplasms; Immunotherapy; Molecular targeted therapy; Chimeric antigen receptor","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"457-461"},"PeriodicalIF":0.0,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49008664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.05.015
Zhengna Yin, G. Zhang, H. Meng, Wei Yang, Yicheng Wang
Acquired severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome. Immunosuppressive therapy (IST) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) are the main treatments for acquired SAA. Matched sibling donor (MSD)-hematopoietic stem cell transplantation (HSCT) is the best treatment for acquired SAA patients who are younger than 40 years old. Outcomes of unrelated donor (URD)-HSCT, haploidentical hematopoietic stem cell transplantation (haplo-HSCT) and umbilical cord blood transplantation (UCBT) have improved in the recent decade, and provide more options with respect to the clinical treatment of acquired SAA. In order to improve clinicians′ understanding of allo-HSCT for acquired SAA, this article reviews the research progress of acquired SAA treated by allo-HSCT in recent years. Key words: Anemia, aplastic; Hematopoietic stem cell transplantation; Donor selection; Transplantation conditioning; Graft vs host disease; Transplantation, haploidentical; Cord blood stem cell transplantation
{"title":"Advances in allogeneic hematopoietic stem cell transplantation in treatment of acquired severe aplastic anemia","authors":"Zhengna Yin, G. Zhang, H. Meng, Wei Yang, Yicheng Wang","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.05.015","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.015","url":null,"abstract":"Acquired severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome. Immunosuppressive therapy (IST) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) are the main treatments for acquired SAA. Matched sibling donor (MSD)-hematopoietic stem cell transplantation (HSCT) is the best treatment for acquired SAA patients who are younger than 40 years old. Outcomes of unrelated donor (URD)-HSCT, haploidentical hematopoietic stem cell transplantation (haplo-HSCT) and umbilical cord blood transplantation (UCBT) have improved in the recent decade, and provide more options with respect to the clinical treatment of acquired SAA. In order to improve clinicians′ understanding of allo-HSCT for acquired SAA, this article reviews the research progress of acquired SAA treated by allo-HSCT in recent years. \u0000 \u0000 \u0000Key words: \u0000Anemia, aplastic; Hematopoietic stem cell transplantation; Donor selection; Transplantation conditioning; Graft vs host disease; Transplantation, haploidentical; Cord blood stem cell transplantation","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"450-456"},"PeriodicalIF":0.0,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41948839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.05.008
Guangxiang Xi, Min-jie Zhou, Lanjiang Zhang, Li Zhong, Shuangli Liu
Objective To explore the influence factors of unqualified alanine aminotransferase (ALT) of voluntary blood donors in Chengdu. Methods From June 1, 2012 to June 1, 2013, a total of 16 424 voluntary blood donors from a street blood collection point of Chengdu Blood Center were selected as subjects by random sampling method. Among them, there were 8 860 male and 7 564 female donors, aged from 18 to 55 years. Blood samples for ALT primary screening were detected by dry chemical method, and blood samples for ALT laboratory re-examination were detected by rate method. The ALT value > 40 U/L was determined to be unqualified for ALT blood screening or laboratory re-examination of blood donors. The information management system of Tangshan Qiao 5.0 was used to collect the data of blood donors including gender, age, height, weight, marital status, nationality, occupation, educational level and the seasons of blood donation. The ALT unqualified rates of blood donors with different demographic characteristics (gender, age, marital status, nationality, occupation and education level), seasons of blood donation and body mass index (BMI) were calculated respectively. Chi-square test was used to compare the ALT unqualified rates of blood donors with different demographic characteristics, seasons of blood donation and BMI. Multivariate unconditional logistic regression analysis was used to further study the independent influence factors of ALT disqualification in voluntary blood donors. The procedures followed in this study were in accordance with the requirements of the World Medical Association Declaration of Helsinki revised in 2013. And the Informed Consent of Blood Donors were signed with all blood donors before blood donation. Results ① Among the 16 424 voluntary donors in this study, and the unqualified rate of ALT was 14.4% (2 363/16 424). Among them, a number of 2 256 donors failed in ALT primary screening, accounting for 95.5% (2 256/2 363); and 107 donors failed in ALT laboratory re-examination, accounting for 4.5% (107/2 363). ② The results of univariate analysis for the influence factors of ALT disqualification in 16 424 voluntary blood donors in this study showed that there were significant differences in ALT unqualified rates among donors of different gender, age, marital status, occupation, education level, seasons of blood donation and BMI, respectively (χ2=872.65, 627.76, 575.94, 641.88, 150.64, 50.71, 2 152.05; P<0.001). ③ The results of multivariate unconditional logistic regression analysis showed that male (OR=3.52, 95%CI: 3.13-3.96, P<0.001), age of 26-35 years (OR=1.25, 95%CI: 1.07-1.46, P<0.001), 18.5 kg/m2 ≤ BMI<25.0 kg/m2 (OR=2.34, 95%CI: 1.24-4.45, P=0.010), 25.0 kg/m2≤BMI<28.0 kg/m2 (OR=7.51, 95%CI: 3.98-14.29, P<0.001) and BMI≥28.0 kg/m2 (OR=19.48, 95%CI: 10.13-37.45, P<0.001); married (OR=1.27, 95%CI: 1.09-1.47, P<0.001); blood donation in summer (OR=1.50, 95%CI: 1.26-1.79, P<0.001), blood donation in autumn (OR=1.79,
{"title":"Analysis of influence factors of alanine transaminase in voluntary blood donors in Chengdu","authors":"Guangxiang Xi, Min-jie Zhou, Lanjiang Zhang, Li Zhong, Shuangli Liu","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.05.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.008","url":null,"abstract":"Objective \u0000To explore the influence factors of unqualified alanine aminotransferase (ALT) of voluntary blood donors in Chengdu. \u0000 \u0000 \u0000Methods \u0000From June 1, 2012 to June 1, 2013, a total of 16 424 voluntary blood donors from a street blood collection point of Chengdu Blood Center were selected as subjects by random sampling method. Among them, there were 8 860 male and 7 564 female donors, aged from 18 to 55 years. Blood samples for ALT primary screening were detected by dry chemical method, and blood samples for ALT laboratory re-examination were detected by rate method. The ALT value > 40 U/L was determined to be unqualified for ALT blood screening or laboratory re-examination of blood donors. The information management system of Tangshan Qiao 5.0 was used to collect the data of blood donors including gender, age, height, weight, marital status, nationality, occupation, educational level and the seasons of blood donation. The ALT unqualified rates of blood donors with different demographic characteristics (gender, age, marital status, nationality, occupation and education level), seasons of blood donation and body mass index (BMI) were calculated respectively. Chi-square test was used to compare the ALT unqualified rates of blood donors with different demographic characteristics, seasons of blood donation and BMI. Multivariate unconditional logistic regression analysis was used to further study the independent influence factors of ALT disqualification in voluntary blood donors. The procedures followed in this study were in accordance with the requirements of the World Medical Association Declaration of Helsinki revised in 2013. And the Informed Consent of Blood Donors were signed with all blood donors before blood donation. \u0000 \u0000 \u0000Results \u0000① Among the 16 424 voluntary donors in this study, and the unqualified rate of ALT was 14.4% (2 363/16 424). Among them, a number of 2 256 donors failed in ALT primary screening, accounting for 95.5% (2 256/2 363); and 107 donors failed in ALT laboratory re-examination, accounting for 4.5% (107/2 363). ② The results of univariate analysis for the influence factors of ALT disqualification in 16 424 voluntary blood donors in this study showed that there were significant differences in ALT unqualified rates among donors of different gender, age, marital status, occupation, education level, seasons of blood donation and BMI, respectively (χ2=872.65, 627.76, 575.94, 641.88, 150.64, 50.71, 2 152.05; P<0.001). ③ The results of multivariate unconditional logistic regression analysis showed that male (OR=3.52, 95%CI: 3.13-3.96, P<0.001), age of 26-35 years (OR=1.25, 95%CI: 1.07-1.46, P<0.001), 18.5 kg/m2 ≤ BMI<25.0 kg/m2 (OR=2.34, 95%CI: 1.24-4.45, P=0.010), 25.0 kg/m2≤BMI<28.0 kg/m2 (OR=7.51, 95%CI: 3.98-14.29, P<0.001) and BMI≥28.0 kg/m2 (OR=19.48, 95%CI: 10.13-37.45, P<0.001); married (OR=1.27, 95%CI: 1.09-1.47, P<0.001); blood donation in summer (OR=1.50, 95%CI: 1.26-1.79, P<0.001), blood donation in autumn (OR=1.79, ","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"413-419"},"PeriodicalIF":0.0,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45759997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The patient blood management (PBM) is an evidence-based care policy made by the multi-disciplinary teams designed to maintain hemoglobin(Hb) concentration, optimize hemostasis and minimize blood loss in an effort to improve patients′ outcomes. Patients undergoing elective orthopedic surgery usually suffer from large blood loss and high incidence of blood transfusion. Therefore, the PBM in elective orthopedic surgery has become a common concern of clinical multi-disciplinary teams such as transfusion, anesthesiology and surgery. This article reviews the research status of the implement of PBM in elective orthopedic surgery in 3 aspects including anemia management, decrease of blood loss and reasonable blood transfusion. Key words: Blood transfusion; Blood transfusion, autologous; Anemia; Blood loss, surgical; Patient blood management; Orthopedic surgery
{"title":"Implement of patient blood management in elective orthopedic surgery","authors":"Yaxin Fan, Xiaolin Bi, Shuang Xu, Molin Wang, Zhi-Yan Qi","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.05.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.002","url":null,"abstract":"The patient blood management (PBM) is an evidence-based care policy made by the multi-disciplinary teams designed to maintain hemoglobin(Hb) concentration, optimize hemostasis and minimize blood loss in an effort to improve patients′ outcomes. Patients undergoing elective orthopedic surgery usually suffer from large blood loss and high incidence of blood transfusion. Therefore, the PBM in elective orthopedic surgery has become a common concern of clinical multi-disciplinary teams such as transfusion, anesthesiology and surgery. This article reviews the research status of the implement of PBM in elective orthopedic surgery in 3 aspects including anemia management, decrease of blood loss and reasonable blood transfusion. \u0000 \u0000 \u0000Key words: \u0000Blood transfusion; Blood transfusion, autologous; Anemia; Blood loss, surgical; Patient blood management; Orthopedic surgery","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"374-379"},"PeriodicalIF":0.0,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48959717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：